ABUS vs ROL · P/E 5.4, rev $6.2M vs P/E 41, rev $3.39B
Arbutus Biopharma Corp (ABUS) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported ROL revenue for 2024-12-31 was $3.39B. Net income was $466.4M. Revenue was up 10.3% from 2023-12-31 to 2024-12-31. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the ABUS and ROL stock pages for the full models.
Not investment advice.